Eric Messner – CEO
Eric Messner is CEO at Emalex Biosciences. He is also Senior Vice President of Business Development at Paragon Biosciences, where he identifies opportunities, completes due diligence and integrates new products and companies into the Paragon portfolio.
Mr. Messner has an extensive, successful career in the biopharmaceutical industry. Formerly, he was Vice President of Sales and Marketing for Marathon Pharmaceuticals. Before that, Mr. Messner was CEO of Anagin, and also served as General Manager and Executive Vice President of Sales and Marketing for OPKO Health. Earlier in his career, he was a founder and Vice President of Marketing and Commercial Operations of Proventiv Therapeutics, which was acquired by Cytochroma. At Cytochroma, he was Vice President of Commercial Operations, later Chief Operating Officer and helped lead the sale of Cytochroma to OPKO Health. Mr. Messner also previously held senior marketing roles at Bone Care International and Abbott Laboratories. Mr. Messner earned his MBA from Northwestern University’s Kellogg School of Management and his Bachelor of Science in Business Administration from Miami University.